| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 156, Issue 8 2840-2850, Copyright © 1996 by American Association of Immunologists
ARTICLES |
VL Pulito, VA Roberts, JR Adair, AL Rothermel, AM Collins, SS Varga, C Martocello, M Bodmer, LK Jolliffe and RA Zivin
Drug Discovery, R.W. Johnson Pharmaceutical Research Institute, Raritan, NJ 08869, USA.
OKT4A, a murine mAb that recognizes an epitope on the CD4 receptor, is a potent immunosuppressive agent in vitro and in a variety of nonhuman primate models of graft rejection and autoimmune disease. Initial human cardiac transplant trials suggest that OKT4A does not cause either cytokine release syndrome or CD4+ cell depletion, but does induce a human anti-mouse Ab (HAMA) response despite strong concurrent immunosuppression. To further investigate the potential of OKT4A as an immunomodulator, it was necessary to decrease its immunogenicity. Therefore, we developed a humanized version of this Ab (gOKT4A-4), which has the same binding affinity and in vitro immunosuppressive properties of OKT4A, but retains only three murine sequence-derived amino acid residues outside of the complementarity-determining regions (CDRs). Detailed computer modeling of both OKT4A and gOKT4A-4 provided a computational rationale for the changes necessary to regain activity after humanization. This has also provided a plausible representation of the Ag binding site. Preliminary clinical results with gOKT4A-4 suggest that we have eliminated the immunogenicity observed in the parent murine Ab.
This article has been cited by other articles:
|
|
 |
|
  S. Hou, B. Li, L. Wang, W. Qian, D. Zhang, X. Hong, H. Wang, and Y. Guo Humanization of an Anti-CD34 Monoclonal Antibody by Complementarity-determining Region Grafting Based on Computer-assisted Molecular Modelling J. Biochem., July 1, 2008; 144(1): 115 - 120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Chentouf, S. Ghannam, C. Bes, S. Troadec, M. Cerutti, and T. Chardes Recombinant Anti-CD4 Antibody 13B8.2 Blocks Membrane-Proximal Events by Excluding the Zap70 Molecule and Downstream Targets SLP-76, PLC{gamma}1, and Vav-1 from the CD4-Segregated Brij 98 Detergent-Resistant Raft Domains J. Immunol., July 1, 2007; 179(1): 409 - 420. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bes, L. Briant-Longuet, M. Cerutti, F. Heitz, S. Troadec, M. Pugniere, F. Roquet, F. Molina, F. Casset, D. Bresson, et al. Mapping the Paratope of Anti-CD4 Recombinant Fab 13B8.2 by Combining Parallel Peptide Synthesis and Site-directed Mutagenesis J. Biol. Chem., April 11, 2003; 278(16): 14265 - 14273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Clarke, F.-T. Lee, M. W. Brechbiel, F. E. Smyth, L. J. Old, and A. M. Scott In Vivo Biodistribution of a Humanized Anti-Lewis Y Monoclonal Antibody (hu3S193) in MCF-7 Xenografted BALB/c Nude Mice Cancer Res., September 1, 2000; 60(17): 4804 - 4811. [Abstract] [Full Text]
|
|
|
|
|
|
M. P. Reddy, C. A. S. Kinney, M. A. Chaikin, A. Payne, J. Fishman-Lobell, P. Tsui, P. R. Dal Monte, M. L. Doyle, M. R. Brigham-Burke, D. Anderson, et al. Elimination of Fc Receptor-Dependent Effector Functions of a Modified IgG4 Monoclonal Antibody to Human CD4 J. Immunol., February 15, 2000; 164(4): 1925 - 1933. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Baca, L. G. Presta, S. J. O'Connor, and J. A. Wells Antibody Humanization Using Monovalent Phage Display J. Biol. Chem., April 18, 1997; 272(16): 10678 - 10684. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
